

From: s 22
To: s 22
Subject: FW: Seeking clearance: Request for Action - EM 2024/17 - 2023-24 Preliminary End of Financial Year Reporting Requirements [SEC=PROTECTED]
Date: Thursday, 18 July 2024 9:15:01 AM
Attachments: [image001.png](#)
[image002.png](#)
[2023-24 HEALTH ADMIN PreliminaryCashVariances - PBS AAU edits.xlsx](#)
[RE Seeking clearance Request for Action - EM 2024/17 - 2023-24 Preliminary End of Financial Year Reporting Requirements SECOFFICIAL.msg](#)

PROTECTED

From: s 22 @finance.gov.au>
Sent: Tuesday, July 2, 2024 2:20 PM
To: s 22 @finance.gov.au>
Subject: FW: Seeking clearance: Request for Action - EM 2024/17 - 2023-24 Preliminary End of Financial Year Reporting Requirements [SEC=PROTECTED]

PROTECTED

H s22

Please see attached the cash payments and receipts variance workbook for your review and clearance, as the explanation for Novavax in payments tab is now updated.

Please note that I have taken a gist of s 22 response as well to provide conclusion to the explanation, and the email is attached.

Many thanks

s22

From: s 22 @protected.health.gov.au>
Sent: Tuesday, July 2, 2024 1:29 PM
To: s 22 @finance.gov.au>; s 22 @finance.gov.au>; PBS Team
s 47E(d) @finance.gov.au>
Cc: s 22 @Protected.Health.gov.au>; Ms 22
@Protected.Health.gov.au>; s 22 @Protected.Health.gov.au>; s 22
@Protected.Health.gov.au>
Subject: FW: Seeking clearance: Request for Action - EM 2024/17 - 2023-24 Preliminary End of Financial Year Reporting Requirements [SEC=OFFICIAL]

HI s22

Please see responses to questions below in blue text.

Best regards,

s22

Administered Accounting Section | Financial Management Division
Australian Government Department of Health
T: s 22 | E: s 22 @health.gov.au

From: s 22 @finance.gov.au>
Sent: Tuesday, 2 July 2024 11:17 AM
To: s 22 @protected.health.gov.au>
Cc: s 22 @Protected.Health.gov.au>; s 22
Y@Protected.Health.gov.au>; s 22 @Protected.Health.gov.au>; s 22
@Protected.Health.gov.au>; s 22 @finance.gov.au>; PBS Team
s 47E(d) @finance.gov.au>
Subject: RE: Seeking clearance: Request for Action - EM 2024/17 - 2023-24 Preliminary End of Financial Year Reporting Requirements [SEC=OFFICIAL]

OFFICIAL

s22
Hi

Thanks very much for coordinating with the policy area for us.

As discussed, we now understand the calculations behind s47 variance, but we would like to seek a bit more clarification in anticipation of our Senior Executives query.

- Can we please understand **why** the Novavax doses are being cancelled? Novavax has been unable to supply due to ceasing manufacturing their ancestral vaccine and experiencing delays with approval of their XBB.1.5 vaccine. While the department has an agreement with Novavax for supply of their COVID-19 vaccine, Novavax ceased manufacturing their original COVID-19 vaccine in early 2023 and the Governments supply has now been exhausted. The TGA commenced evaluating the XBB.1.5 COVID-19 vaccine from Bioelect Pty Ltd (on behalf of Novavax Inc.) on 9 November 2023. Following discussions with the TGA, on 21 May 2024, Bioelect Pty Ltd withdrew this application, meaning that the TGA is no longer evaluating this vaccine for use or supply in Australia. Withdrawal was a decision of the company and any questions relating to the withdrawal should be directed to Bioelect Pty Ltd s22. Registration and supply in Australia will only commence should a vaccine be approved as safe and effective by the TGA. As a result Novavax has failed to meet its commitments s47
- Please confirm if the cancellation of doses has been reported to the Government already, and if not, can Finance please know when is the going to be reported? No, it has not been reported to Government. It will be reported in 2024-25 when negotiations are finalised and an Advance Purchase Agreement amendment has been formalised.
- We note that there are changes in the exchange rate from your response below versus the costing agreed by Finance in 2023-24 Budget. But can we please have your confirmation if an Estimates Variation is needed for this and if so, when are we expecting to see this for Finance's consideration? - 0.6548 exchange rate was provided in the Economic Parameters for MYEFO 2023-24 an Estimates Variation was submitted and approved in MYEFO 2023-24 for the Exchange Rate. Will review whether an EV for exchange rate is required from latest Economic Parameters in MYEFO 2024-25.
- Can we please get clarification on s47 how is this linked back to the variance? - s47

Many thanks

s22

Duplicate of Document 6